By leveraging our expertise in complex, three-dimensional disease models comprised of human cells and complex analytical methods, we are able to drive drug discovery in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients’ lives.  The traditional reliance on animal models of disease today often leads to clinical trial failures due to species differences that prevent accurately reproducing human disease. Viscient is creating a more faithful picture of specific human diseases by relying on human cells and a 3D reconstruction of the tissue to show the truest possible biology in vitro.  Then, our expertise in transcriptomics and other methods allows us to detect genes and pathways that drive disease progression.  These driver genes are critical targets for our drug discovery programs.

 

We are initially conducting discovery and development work in non-alcoholic steatohepatitis (NASH), an area expected to have future drug revenue for pharma of up to $40B per year.  We have achieved disease progression in vitro, identified novel disease-driver gene targets and are moving to build medicinal chemistry to develop drugs that modulate these targets.